Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00— vs Q3 2019 Net Income-$1.25M-$1.25MN/M vs Q3 2019 EPS Diluted-$0.33-$0.33N/M vs Q3 2019 Operating Income-$1,948,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
ended Sep 30, 2020 · filed Oct 29, 2020 · 29 d after period end